BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Episodes
358 episodes
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities, and precision medicines define cardiovascular disease catalysts this year. On the latest B...
•
Season 7
•
Episode 348
•
31:08
Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos
New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted and commercialized. On the latest BioCentury This Week podcast, BioCentury’s analysts
•
Season 7
•
Episode 347
•
29:48
Ep. 346 - 2026 Public Markets Preview
The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode of the BioCentury This Week podcast, Director of Biopharma Intelligence Stephen Hansen and coll...
•
Season 7
•
Episode 346
•
30:54
Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN
Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Seni...
•
Season 7
•
Episode 345
•
30:33
Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation
The J.P. Morgan Healthcare Conference kicked off this week with sunny skies over San Francisco and more financial momentum than the biotech industry has seen in years. On a special “on the road” edition of the BioCentury This Week podcast, reco...
•
Season 7
•
Episode 344
•
43:19
Ep. 343 - JPM Deals, Policy Outlook, Approval Trends
Riding the tailwind of a strong 2H25, the days leading up to biotech’s annual kickoff meeting in San Francisco delivered billions in capital raised and more than two dozen deals announced. On the latest BioCentury This Week podcast, BioCentury’...
•
Season 7
•
Episode 343
•
25:19
Ep. 342 - 2026 Biotech Kickoff
The New Year begins with biotech running along parallel storylines. There’s cause for optimism as the industry’s financing gears have begun to churn again and innovation remains as strong as it has ever been, while there's cause for concern as ...
•
Season 7
•
Episode 342
•
25:54
Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and new leadership at FDA shuffled the regulatory deck. On the latest BioCentury This Week<...
•
Season 6
•
Episode 341
•
38:15
Ep. 340 - Obesity Data, Kymera & FDA Survey Results
Obesity readouts continue to be hot for biotech with new top-line data from both injectable and oral therapies pushing the boundaries on efficacy. On the latest BioCentury This Week podcast, BioCentury’s analysts break down last week’s readouts...
•
Season 6
•
Episode 340
•
32:50
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three weeks to go in the year. On the latest BioCentury This Week, BioCentury’s analysts discuss the rise in lar...
•
Season 6
•
Episode 339
•
35:21
Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding
Novo Nordisk’s highly anticipated data for semaglutide in Alzheimer’s dashed hopes that the GLP-1 therapy could become a game changer in the disease. On the latest BioCentury This Week podcast, Executive Editor Selina Koch discusses th...
•
Season 6
•
Episode 338
•
29:46
Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc
A baffling decision by FDA to issue a complete response letter for a pediatric medicine the medical community stood behind is just the latest example raising concerns that the agency is shifting the regulatory goalposts amid a lack of transpare...
•
Season 6
•
Episode 337
•
33:55
Ep. 336 - Cautious Optimism and M&A Momentum
There is cautious optimism around continued M&A momentum and the public equities markets as biotech heads into the New Year. On a special edition of the BioCentury This Week podcast recorded in London during London Life Sciences Week, BioCe...
•
Season 6
•
Episode 336
•
41:01
Ep. 335 - Neurology's Coming Inflection Point
Voyager CEO and former head of R&D at Biogen Al Sandrock is more optimistic than ever about the prospect of bringing clinically meaningful solutions to patients with Alzheimer’s disease and other neurodegenerative disorders. The threads of ...
•
Season 6
•
Episode 335
•
40:11
Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi
Richard Pazdur took the top job at FDA’s Center for Drug Evaluation and Research after receiving vows that he would be leading CDER free from political interference. On the latest BioC...
•
Season 6
•
Episode 334
•
36:04
Ep. 333 - Is This Korea’s Biotech Moment?
Today’s South Korean biotechs have a risk-on mentality, a willingness to partner, and strategies focused on globalization. On a special edition of the BioCentury This Week podcast recorded at Venture Café Cambridge, BioCentury is joine...
•
Season 6
•
Episode 333
•
45:39
Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA
With ObesityWeek yielding eye-catching amylin data and a bidding war that ran to $10 billion for Metsera, weight loss companies were center stage in biotech last week. On the latest edition of the BioCentury This Week podcast, BioCentu...
•
Season 6
•
Episode 332
•
28:03
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
Novo Nordisk’s unsolicited $8.5 billion bid for Metsera has thrown a wrench into Pfizer’s plans to return to the obesity race via its acquisition of the New York-based start-up. On the latest BioCentury This Week podcast, BioCentury’s ...
•
Season 6
•
Episode 331
•
27:56
Ep. 330 - China's Innovation Moment
China is setting a new bar for the speed of clinical development and redefining the time it takes an asset to get to the clinic. On a special edition of the BioCentury This Week podcast recorded on stage at the 12th BioCentury BayHelix...
•
Season 6
•
Episode 330
•
43:15
Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors
Novartis’ biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish line. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the $12 billion de...
•
Season 6
•
Episode 329
•
31:23
Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers
Next-generation platforms and technologies are getting closer to cracking one of biopharma’s biggest problems: delivering medicines, and mAbs in particular, to the brain. On the latest BioCentury This Week podcast, BioCentury’s Selina ...
•
Season 6
•
Episode 328
•
33:59
Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg
It’s been a tough year for cell and gene therapy — patient deaths, high-profile companies pulling out of the space, and sour investment sentiment. But the field has had some promising readouts in the clinic recently, and it continues to mature,...
•
Season 6
•
Episode 327
•
23:04
Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A
Biotech’s fourth quarter began with a familiar feeling, with indicators pointing toward an improving public market even as political and regulatory uncertainty has buysiders reluctant to say industry has returned to sustainable growth. On the l...
•
Season 6
•
Episode 326
•
36:01
Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund
The short-term consequences for Pfizer from its “most favored nation” drug pricing deal with the White House are negligible, but the long-term effects on the industry could be profound and permanent. On the latest BioCentury This Week
•
Season 6
•
Episode 325
•
30:11
